Search Results 31-40 of 252 for ⌚비아그라구매사이트 【BCBC365.컴】 톌레: VIA36500 톡:VIA3650 골드드래곤구매⌚

  1. A Phase 1 Study Evaluating the Safety, PK, and Clinical Effects of PT-112 in Subjects With Advanced Solid Tumors

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

  2. Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer - Mayo Clinic

    Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells. Binimetinib may stop the growth of tumor ...

  3. A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma - Mayo Clinic

    Study PT-112-102, a multicenter, open-label dose-finding and pharmacokinetic study of PT-112 in patients with relapsed or refractory multiple myeloma. This is ...

  4. Venetoclax and Vincristine Liposomal in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia - Mayo Clinic

    Venetoclax may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as vincristine liposomal ...

  5. Drugs and Supplements that Start with F - Mayo Clinic

    Explore a comprehensive list of prescription and over-the-counter medications starting with the letter “F” to learn about drug side effects, proper use and ...

  6. Fidanacogene elaparvovec-dzkt (intravenous route) - Side effects & uses - Mayo Clinic

    Description. Fidanacogene elaparvovec-dzkt injection is used to treat moderate to severe hemophilia B (congenital Factor IX deficiency) in patients who are ...

  7. Drugs and Supplements that Start with V - Mayo Clinic

    Explore a comprehensive list of prescription and over-the-counter medications starting with the letter “V” to learn about drug side effects, proper use and ...

  8. A Study to Evaluate Ulixertinib to Treat Patients with Advanced Malignancies Harboring MEK or Atypical BRAF Alterations - Mayo Clinic

    Early clinical data have demonstrated anti-tumor activity with ulixertinib treatment and have identified specific groups of patients for whom additional ...

  9. Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma - Mayo Clinic

    The purpose of this study is to compare the effect of treatment with palbociclib alone to treatment with palbociclib plus cemiplimab for treating patients with ...

  10. A Study to Assess the Safety and Dose Escalation of Pegtomarginase (PT01) for Subjects with Advanced Malignancies - Mayo Clinic

    The purpose of this first-in-human (FIH) study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity ...